1 - 25 of 26 results for author:"Jensen M.R." in Literature citations
Results Customize
› Repeat search in UniProtKB (14)
| Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. Davies N.G., Browne H., Davis B., Drysdale M.J., Foloppe N., Geoffrey S., Gibbons B., Hart T., Hubbard R., Jensen M.R. et al. Bioorg. Med. Chem. 20:6770-6789(2012) · Mapped (1) |
| The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Menezes D.L., Taverna P., Jensen M.R., Abrams T., Stuart D., Yu G.K., Duhl D., Machajewski T., Sellers W.R., Pryer N.K. et al. Mol. Cancer Ther. 11:730-739(2012) · Mapped (8) |
| Pilotin-secretin recognition in the type II secretion system of Klebsiella oxytoca. Tosi T., Nickerson N.N., Mollica L., Jensen M.R., Blackledge M., Baron B., England P., Pugsley A.P., Dessen A. Mol. Microbiol. 82:1422-1432(2011) · UniProtKB (1) · Mapped (1) |
| Structure of the vesicular stomatitis virus N⁰-P complex. Leyrat C., Yabukarski F., Tarbouriech N., Ribeiro E.A. Jr., Jensen M.R., Blackledge M., Ruigrok R.W., Jamin M. PLoS Pathog. 7:e1002248-e1002248(2011) · UniProtKB (2) |
| Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. Guagnano V., Furet P., Spanka C., Bordas V., Le Douget M., Stamm C., Brueggen J., Jensen M.R., Schnell C., Schmid H. et al. J. Med. Chem. 54:7066-7083(2011) · Mapped (1) |
| A thermodynamic switch modulates abscisic acid receptor sensitivity. Dupeux F., Santiago J., Betz K., Twycross J., Park S.Y., Rodriguez L., Gonzalez-Guzman M., Jensen M.R., Krasnogor N., Blackledge M. et al. EMBO J. 30:4171-4184(2011) · Mapped (2) |
| Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. Brough P.A., Barril X., Borgognoni J., Chene P., Davies N.G., Davis B., Drysdale M.J., Dymock B., Eccles S.A., Garcia-Echeverria C. et al. J. Med. Chem. 52:4794-4809(2009) · Mapped (1) |
| Solution structure of a conformationally restricted fully active derivative of the human relaxin-like factor. Bullesbach E.E., Hass M.A., Jensen M.R., Hansen D.F., Kristensen S.M., Schwabe C., Led J.J. Biochemistry 47:13308-13317(2008) · UniProtKB (1) |
| Weak self-association of human growth hormone investigated by nitrogen-15 NMR relaxation. Jensen M.R., Kristensen S.M., Keeler C., Christensen H.E., Hodsdon M.E., Led J.J. Proteins 73:161-172(2008) · Mapped (7) |
| Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Wells M., Tidow H., Rutherford T.J., Markwick P., Jensen M.R., Mylonas E., Svergun D.I., Blackledge M., Fersht A.R. Proc. Natl. Acad. Sci. U.S.A. 105:5762-5767(2008) · Mapped (32) |
| Comparison of different signal peptides for secretion of heterologous proteins in fission yeast. Kjaerulff S., Jensen M.R. Biochem. Biophys. Res. Commun. 336:974-982(2005) · Mapped (1) |
| Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. Pasini D., Bracken A.P., Jensen M.R., Lazzerini Denchi E., Helin K. |
| The negative role of cyclin G in ATM-dependent p53 activation. Ohtsuka T., Jensen M.R., Kim H.G., Kim K.T., Lee S.W. Oncogene 23:5405-5408(2004) · Mapped (3) |
| E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. Di Stefano L., Jensen M.R., Helin K. EMBO J. 22:6289-6298(2003) · UniProtKB (1) |
| Reduced hepatic tumor incidence in cyclin G1-deficient mice. Jensen M.R., Factor V.M., Fantozzi A., Helin K., Huh C.G., Thorgeirsson S.S. Hepatology 37:862-870(2003) · Mapped (8) |
| Cyclin G recruits PP2A to dephosphorylate Mdm2. Okamoto K., Li H., Jensen M.R., Zhang T., Taya Y., Thorgeirsson S.S., Prives C. Mol. Cell 9:761-771(2002) · Mapped (28) |
| In vivo expression and genomic organization of the mouse cyclin I gene (Ccni). Jensen M.R., Audolfsson T., Factor V.M., Thorgeirsson S.S. |
| Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption. Santoni-Rugiu E., Jensen M.R., Factor V.M., Thorgeirsson S.S. Am. J. Pathol. 154:1693-1700(1999) · Mapped (15) |
| Gene structure and chromosomal localization of mouse cyclin G2 (Ccng2). Jensen M.R., Audolfsson T., Keck C.L., Zimonjic D.B., Thorgeirsson S.S. |
| Assignment of the cyclin I gene (Ccni) to mouse chromosome 5E3.3-F1. 3 by in situ hybridization. Jensen M.R., Audolfsson T., Keck C.L., Zimonjic D.B., Thorgeirsson S.S. Cytogenet. Cell Genet. 83:242-243(1998) · UniProtKB (1) · Mapped (4) |
| Regulation of cyclin G1 during murine hepatic regeneration following Dipin-induced DNA damage. Jensen M.R., Factor V.M., Thorgeirsson S.S. Hepatology 28:537-546(1998) · UniProtKB (1) |
| Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Santoni-Rugiu E., Jensen M.R., Thorgeirsson S.S. Cancer Res. 58:123-134(1998) · Mapped (18) |
| Chromosome localization and structure of the murine cyclin G1 gene promoter sequence. Jensen M.R., Factor V.M., Zimonjic D.B., Miller M.J., Keck C.L., Thorgeirsson S.S. |
| Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Factor V.M., Kao C.Y., Santoni-Rugiu E., Woitach J.T., Jensen M.R., Thorgeirsson S.S. Cancer Res. 57:2089-2095(1997) · Mapped (10) |
| Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Santoni-Rugiu E., Nagy P., Jensen M.R., Factor V.M., Thorgeirsson S.S. Am. J. Pathol. 149:407-428(1996) · Mapped (15) |